Fig. 1

Efficacy end points in 3-year follow-up in RAY study: a Progression-free survival for ibrutinib and temsirolimus by prior line of therapy; b Overall survival for ibrutinib and temsirolimus by prior line of therapy; c Duration of clinical response by prior line of therapy in patients randomized to ibrutinib; d Time to second progression or death for ibrutinib and temsirolimus